The role of <i>Helicobacter pylori</i> in metabolic and cardiovascular diseases

Abstract

Helicobacter pylori (H. pylori) infection is one of the most common in the world. More than 50% of the world’s population is infected and infection rates are especially high in countries with poor socio-economic conditions. H. pylori causes gastroduodenal and extra-gastroduodenal diseases including such metabolic disorders as obesity, diabetes mellitus and non-alcoholic fatty liver disease. Recent epidemiological and clinical studies showed that the long-term persistence of H. pylori infection is associated with the development and progression of atherosclerosis and consequently cardiovascular diseases. However, the correlation between these conditions is ambiguous and there is not enough evidence to confirm it. The lack of consensus might be related to differences in diagnostic methods used for H. pylori and the variety of its genotypes. Considering high prevalence of H. pylori infection as well as high incidence of metabolic and cardiovascular diseases, a verified correlation between these can be of great epidemiological, prophylactic and clinical significance.

Endoscopic evaluation of gastric mucosal alterations in patients with chronic heart failure II-III nyha functional class utilizing advanced endoscopic techniques

“…В развитии очаговых изменений и эрозивных поражений СОЖ, в том числе у пациентов с ХСН, доказана этиологическая роль Helicobacter pylori (Hp) [11,25,26,27]. Так ж е учеными установлена корреляция между сердечно-сосудистыми факторами риска, маркерами воспалительных процессов при атеросклеротическом процессе и Hр, приводящая к прогрессированию и дестабилизации атеросклеротических бляшек и развитию ишемической болезни сердца [28][29][30][31]. В странах, где на фоне эрадикации Hp наблюдается снижение уровня распространенности этой бактерии, актуальным становится вопрос о влиянии желчных кислот на развитие очаговых изменений СОЖ, и как следствие, их роли в канцерогенезе [32,33].…”